BR112012014180A2 - composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio. - Google Patents
composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio.Info
- Publication number
- BR112012014180A2 BR112012014180A2 BR112012014180A BR112012014180A BR112012014180A2 BR 112012014180 A2 BR112012014180 A2 BR 112012014180A2 BR 112012014180 A BR112012014180 A BR 112012014180A BR 112012014180 A BR112012014180 A BR 112012014180A BR 112012014180 A2 BR112012014180 A2 BR 112012014180A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- disease
- treating
- disorder
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28753509P | 2009-12-17 | 2009-12-17 | |
PCT/US2010/060007 WO2011084368A1 (en) | 2009-12-17 | 2010-12-13 | Quinoline amide m1 receptor positive allosteric modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012014180A2 true BR112012014180A2 (pt) | 2015-09-15 |
Family
ID=44305688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012014180A BR112012014180A2 (pt) | 2009-12-17 | 2010-12-13 | composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio. |
Country Status (41)
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
BR112012020142A2 (pt) * | 2010-02-11 | 2020-08-18 | Northwestern University | moduladores do receptor de nmda com estrutura secundária estabilizada e usos dos mesmos. |
SG185594A1 (en) | 2010-05-17 | 2012-12-28 | Envivo Pharmaceuticals Inc | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate |
US8815902B2 (en) | 2010-06-15 | 2014-08-26 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide M1 receptor positive allosteric modulators |
US8940765B2 (en) * | 2011-05-17 | 2015-01-27 | Merck Sharp & Dohme Corp. | N-linked quinolineamide M1 receptor positive allosteric modulators |
JP6211509B2 (ja) | 2012-03-02 | 2017-10-11 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
EP2846796A4 (en) | 2012-05-08 | 2015-10-21 | Forum Pharmaceuticals Inc | METHODS OF MAINTAINING, PROCESSING OR ENHANCING COGNITIVE FUNCTION |
WO2014077401A1 (ja) | 2012-11-19 | 2014-05-22 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
TW201512197A (zh) * | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
KR20160044039A (ko) | 2013-09-27 | 2016-04-22 | 에프. 호프만-라 로슈 아게 | 인돌 및 인다졸 유도체 |
GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
CN105793259A (zh) * | 2014-01-22 | 2016-07-20 | 豪夫迈·罗氏有限公司 | 氟-萘基衍生物 |
JP6571077B2 (ja) * | 2014-06-13 | 2019-09-04 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
WO2016009297A1 (en) * | 2014-07-18 | 2016-01-21 | Pfizer Inc. | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators |
PE20180252A1 (es) | 2015-06-09 | 2018-02-02 | Bayer Pharma AG | Moduladores alostericos positivos del receptor muscarinico m2 |
JP6553811B2 (ja) * | 2015-09-10 | 2019-07-31 | スヴェン・ライフ・サイエンシズ・リミテッド | ムスカリンm1受容体ポジティブアロステリックモジュレーターとしてのフルオロインドール誘導体 |
WO2017099969A1 (en) * | 2015-12-10 | 2017-06-15 | Merck Sharp & Dohme Corp. | Tetrahydroquinoxaline m1 receptor positive allosteric modulators |
WO2017143041A1 (en) * | 2016-02-16 | 2017-08-24 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
WO2017151449A1 (en) * | 2016-03-04 | 2017-09-08 | Merck Sharp & Dohme Corp. | M1 receptor positive allosteric modulator compounds and methods of use thereof |
JP2019524722A (ja) | 2016-07-11 | 2019-09-05 | バイエル・ファルマ・アクティエンゲゼルシャフト | 7−置換1−ピリジル−ナフチリジン−3−カルボン酸アミドおよびその使用 |
SI3507289T1 (sl) * | 2016-09-02 | 2020-11-30 | Suven Life Sciences Limited, | Pozitivni alosterični modulatorji muskarinskih M1 receptorjev |
JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
US10899759B2 (en) | 2016-09-30 | 2021-01-26 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 |
EA035599B1 (ru) * | 2017-04-13 | 2020-07-14 | Сувен Лайф Сайенсиз Лимитед | Позитивные аллостерические модуляторы мускариновых m1-рецепторов |
SI3643718T1 (sl) | 2017-06-20 | 2023-11-30 | Takeda Pharmaceutical Company Limited | Heterociklična spojina in njena uporaba kot pozitivni alosterični modulator holinergičnega muskarinskega receptorja M1 |
MX2019015747A (es) * | 2017-06-20 | 2020-02-20 | Takeda Pharmaceuticals Co | Compuesto heterociclico. |
EA202090995A1 (ru) * | 2017-10-27 | 2020-07-15 | Сувен Лайф Сайенсиз Лимитед | Полициклические амиды в качестве положительных аллостерических модуляторов мускариновых рецепторов м1 |
US11970483B2 (en) | 2018-09-28 | 2024-04-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
EP3858823A4 (en) | 2018-09-28 | 2022-07-06 | Takeda Pharmaceutical Company Limited | CONDENSED CYCLIC COMPOUND |
MX2021004471A (es) | 2018-10-17 | 2021-08-24 | Suven Life Sciences Ltd | Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1. |
WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
WO2002018344A1 (fr) * | 2000-08-29 | 2002-03-07 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveaux derives esteriques ou amidiques |
WO2004073639A2 (en) | 2003-02-19 | 2004-09-02 | Merck & Co. Inc. | Treatment of psychosis with a muscarinic m1 receptor ectopic activator |
WO2004080463A1 (en) | 2003-03-10 | 2004-09-23 | Schering Corporation | Heterocyclic kinase inhibitors: methods of use and synthesis |
SE0302139D0 (sv) * | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
DK1701951T3 (da) * | 2003-12-23 | 2010-06-07 | Serodus As | Modulatorer af perifere 5-HT receptorer |
EP1725240A4 (en) * | 2004-03-17 | 2009-03-25 | Glaxo Group Ltd | ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR |
EP1963271B1 (en) * | 2005-12-05 | 2010-07-28 | Merck Sharp & Dohme Corp. | Quinolone m1 receptor positive allosteric modulators |
CN101321733A (zh) * | 2005-12-05 | 2008-12-10 | 默克公司 | 喹诺酮m1受体阳性变构调节剂 |
US8106073B2 (en) * | 2007-11-30 | 2012-01-31 | Astrazeneca Ab | Quinoline derivatives 057 |
AU2009225883A1 (en) * | 2008-03-21 | 2009-09-24 | Merck Sharp & Dohme Corp. | Quinolizidinone M1 receptor positive allosteric modulators |
KR101305590B1 (ko) | 2008-11-20 | 2013-09-09 | 머크 샤프 앤드 돔 코포레이션 | 아릴 메틸 벤조퀴나졸리논 m1 수용체 양성 알로스테릭 조절제 |
WO2010096338A1 (en) | 2009-02-23 | 2010-08-26 | Merck Sharp & Dohme Corp. | PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS |
EP2421366B1 (en) | 2009-04-20 | 2013-08-28 | Merck Sharp & Dohme Corp. | Heterocyclic fused cinnoline m1 receptor positive allosteric modulators |
RU2507204C2 (ru) | 2009-08-31 | 2014-02-20 | Мерк Шарп И Доум Корп. | Положительные аллостерические модуляторы м1-рецепторов на основе пираниларилметилбензохиназолинона |
WO2011049731A1 (en) | 2009-10-21 | 2011-04-28 | Merck Sharp & Dohme Corp. | Quinolinone-pyrazolone m1 receptor positive allosteric modulators |
EP2501231B1 (en) | 2009-11-20 | 2016-12-21 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
EP2512245B1 (en) | 2009-12-14 | 2014-07-23 | Merck Sharp & Dohme Corp. | Pyridoquinazolinone m1 receptor positive allosteric modulators |
EP2515656B1 (en) | 2009-12-21 | 2014-08-06 | Merck Sharp & Dohme Corp. | Aminobenzoquinazolinone m1 receptor positive allosteric modulators |
US8883850B2 (en) | 2010-05-28 | 2014-11-11 | Merck Sharp & Dohme Corp. | Naphthalene carboxamide M1 receptor positive allosteric modulators |
US8815902B2 (en) | 2010-06-15 | 2014-08-26 | Merck Sharp & Dohme Corp. | Tetrahydroquinoline amide M1 receptor positive allosteric modulators |
US8557992B2 (en) | 2010-06-15 | 2013-10-15 | Merck Sharp & Dohme Corp. | Heterocyclic fused phenanthrolinone M1 receptor positive allosteric modulators |
US8940765B2 (en) | 2011-05-17 | 2015-01-27 | Merck Sharp & Dohme Corp. | N-linked quinolineamide M1 receptor positive allosteric modulators |
-
2010
- 2010-12-13 HU HUE10841821A patent/HUE029734T2/en unknown
- 2010-12-13 CA CA2782347A patent/CA2782347C/en not_active Expired - Fee Related
- 2010-12-13 EA EA201290519A patent/EA022494B1/ru not_active IP Right Cessation
- 2010-12-13 KR KR1020127015521A patent/KR101494059B1/ko active IP Right Grant
- 2010-12-13 MX MX2012007013A patent/MX336774B/es unknown
- 2010-12-13 GE GEAP201012786A patent/GEP201606506B/en unknown
- 2010-12-13 UA UAA201208772A patent/UA106406C2/ru unknown
- 2010-12-13 PL PL10841821.1T patent/PL2512243T3/pl unknown
- 2010-12-13 NZ NZ600674A patent/NZ600674A/xx not_active IP Right Cessation
- 2010-12-13 CN CN201080057292.2A patent/CN102651970B/zh not_active Expired - Fee Related
- 2010-12-13 EP EP10841821.1A patent/EP2512243B1/en active Active
- 2010-12-13 JP JP2012544670A patent/JP5651708B2/ja not_active Expired - Fee Related
- 2010-12-13 MA MA35061A patent/MA33920B1/fr unknown
- 2010-12-13 PT PT108418211T patent/PT2512243E/pt unknown
- 2010-12-13 PE PE2012000830A patent/PE20121613A1/es not_active Application Discontinuation
- 2010-12-13 US US13/515,724 patent/US9199939B2/en active Active
- 2010-12-13 DK DK10841821.1T patent/DK2512243T3/en active
- 2010-12-13 SI SI201031184A patent/SI2512243T1/sl unknown
- 2010-12-13 SG SG2012044095A patent/SG181719A1/en unknown
- 2010-12-13 ES ES10841821.1T patent/ES2575154T3/es active Active
- 2010-12-13 ME MEP-2016-106A patent/ME02421B/me unknown
- 2010-12-13 RS RS20160369A patent/RS54798B1/sr unknown
- 2010-12-13 AU AU2010340142A patent/AU2010340142B2/en not_active Ceased
- 2010-12-13 WO PCT/US2010/060007 patent/WO2011084368A1/en active Application Filing
- 2010-12-13 BR BR112012014180A patent/BR112012014180A2/pt active Search and Examination
- 2010-12-16 TW TW099144262A patent/TWI412525B/zh not_active IP Right Cessation
- 2010-12-17 AR ARP100104723A patent/AR079510A1/es unknown
-
2012
- 2012-05-17 TN TNP2012000231A patent/TN2012000231A1/en unknown
- 2012-06-03 IL IL220130A patent/IL220130A0/en unknown
- 2012-06-12 ZA ZA2012/04313A patent/ZA201204313B/en unknown
- 2012-06-14 CL CL2012001605A patent/CL2012001605A1/es unknown
- 2012-06-14 HN HN2012001265A patent/HN2012001265A/es unknown
- 2012-06-15 CR CR20120327A patent/CR20120327A/es unknown
- 2012-06-15 CO CO12101581A patent/CO6551729A2/es unknown
- 2012-06-15 NI NI201200107A patent/NI201200107A/es unknown
- 2012-06-15 GT GT201200201A patent/GT201200201A/es unknown
- 2012-06-15 DO DO2012000167A patent/DOP2012000167A/es unknown
- 2012-06-19 EC ECSP12011983 patent/ECSP12011983A/es unknown
- 2012-10-30 HK HK12110914.8A patent/HK1170122A1/zh not_active IP Right Cessation
-
2015
- 2015-11-18 US US14/945,005 patent/US20160075656A1/en not_active Abandoned
-
2016
- 2016-05-27 HR HRP20160574TT patent/HRP20160574T1/hr unknown
- 2016-07-05 CY CY20161100625T patent/CY1117726T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012014180A2 (pt) | composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio. | |
BR112012003464B8 (pt) | compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica | |
BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
HK1154587A1 (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
BR112014012056A8 (pt) | compostos farmacêuticos | |
EP2582676A4 (en) | POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS | |
ATE530544T1 (de) | Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren | |
EA201171197A8 (ru) | Замещенные производные азоантрацена, фармацевтические композиции и способы их применения | |
BR112013006344A2 (pt) | lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas | |
EA201200176A1 (ru) | Производные оксазина и их применение для лечения неврологических нарушений | |
BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112015031903A2 (pt) | composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto | |
UA111579C2 (uk) | ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ | |
BR112013026308A2 (pt) | Compostos de benzeno substituídos | |
BR112015022096A8 (pt) | compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos | |
EA201071045A1 (ru) | Соединения оксадиазоантрацена для лечения диабета | |
MX2013004329A (es) | 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3. | |
BR112014006763A2 (pt) | n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1 | |
EA200970065A1 (ru) | Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38 | |
BR112017012588A2 (pt) | compostos heteroaril-heteroarila bicíclicos de ácido benzoico como agonistas de receptores beta do ácido retinoico (rarbeta) | |
BR112015004306A2 (pt) | fluorometil-substituído pirrol carboxamidas | |
BR112013030391A2 (pt) | derivados de piperidina 3- espirocíclicos como agonistas dos receptores de grelina | |
EA201492097A1 (ru) | 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1 | |
BR112012031634A2 (pt) | composto, composição farmacêutica, uso de um composto, e método para tratar um paciente que sofre de ou susceptível a um distúrbio | |
ATE552257T1 (de) | Positive allosterische chinolizidinon-m1- rezeptormodulatoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: SCHERING CORPORATION (US) |
|
B25D | Requested change of name of applicant approved |
Owner name: MERCK SHARP AND DOHME CORP (US) |
|
B25G | Requested change of headquarter approved |
Owner name: MERCK SHARP AND DOHME CORP (US) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |